5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 118.56▲ | 118.12▲ | 117.94▲ | 117.06▲ | 127.21▼ |
MA10 | 118.30▲ | 117.67▲ | 117.10▲ | 117.54▲ | 134.43▼ |
MA20 | 118.25▲ | 117.06▲ | 117.13▲ | 127.45▼ | 141.15▼ |
MA50 | 117.76▲ | 117.38▲ | 116.19▲ | 135.80▼ | 178.10▼ |
MA100 | 117.05▲ | 116.14▲ | 122.27▼ | 143.23▼ | 213.78▼ |
MA200 | 117.03▲ | 123.53▼ | 132.04▼ | 170.50▼ | 236.27▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.021▲ | 0.195▲ | 0.181▲ | -0.685▼ | -0.558▼ |
RSI | 61.994▲ | 60.229▲ | 57.073▲ | 38.119▼ | 27.724▼ |
STOCH | 81.968▲ | 84.599▲ | 86.992▲ | 31.234 | 24.307 |
WILL %R | -10.714▲ | -2.332▲ | -2.332▲ | -69.337 | -81.777▼ |
CCI | 91.587 | 123.433▲ | 133.504▲ | -46.592 | -175.905▼ |
Wednesday, April 16, 2025 10:26 AM
Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer's treatment.
|
Wednesday, April 16, 2025 02:32 AM
The European Commission (EC) has at last granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU).
|
Tuesday, April 15, 2025 04:00 PM
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
17/04/25 | 115.02 | 118.77 | 114.66 | 118.61 | 1,206,300 |
16/04/25 | 117.00 | 118.00 | 114.96 | 115.29 | 1,341,100 |
15/04/25 | 118.81 | 119.93 | 116.61 | 116.98 | 1,030,700 |
14/04/25 | 116.51 | 119.99 | 115.38 | 119.26 | 1,687,600 |
11/04/25 | 114.32 | 116.39 | 112.18 | 115.17 | 1,618,700 |
10/04/25 | 117.45 | 118.36 | 110.24 | 113.38 | 2,194,706 |
09/04/25 | 110.31 | 121.075 | 110.035 | 120.49 | 3,205,160 |
08/04/25 | 119.77 | 120.79 | 112.88 | 114.05 | 2,090,500 |
07/04/25 | 121.81 | 123.77 | 117.40 | 119.19 | 2,455,900 |
04/04/25 | 129.22 | 129.95 | 122.77 | 122.98 | 3,089,900 |
|
|
||||
|
|
||||
|
|